Stay Informed on Key Developments

Investor News and Updates

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

261 - 270of 392 News

November 04, 2019

Bayer completes sale of Dr. Scholl’s™ brand to Yellow Wood Partners

October 30, 2019

Third quarter of 2019

Bayer: Encouraging business performance across all divisions - agreements signed to divest Currenta and Animal Health

October 14, 2019

Not intended for U.S. and UK Media

U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patients

October 01, 2019

Ertharin Cousin to become member of Bayer AG Supervisory Board

September 28, 2019

Not intended for U.S. and UK Media - European Society for Medical Oncology (ESMO) Congress 2019

Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer

September 23, 2019

Not intended for U.S. and UK Media

Vitrakvi® (larotrectinib) receives first tumor-agnostic approval in EU

September 20, 2019

Not intended for U.S. and UK Media - European Society for Medical Oncology (ESMO) Congress 2019

Bayer data at ESMO 2019 highlights innovation in cancer research

September 10, 2019

Changes to Board of Management structure as of January 1, 2020:

Bayer reduces size of Board of Management from seven to five members

September 02, 2019

Not intended for U.S. and UK Media - New guidelines from the European Society of Cardiology (ESC):

Xarelto™ 2.5 mg plus aspirin recommended for patients at high risk of heart attacks, strokes and death due to chronic coronary syndromes

September 02, 2019

Bayer completes sale of iconic Coppertone™ brand to Beiersdorf

Inform Yourself on Special Topics

Investor News and Updates

Control Weeds, Not Farming

Everything You Need to Know About Glyphosate

Managing Glyphosate Litigation

Managing and Mitigating PCB Litigation Risk